November 04, 2024
Developing treatments for people with mental health conditions
October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
October 08, 2024
Boehringer receives U.S. FDA Breakthrough Therapy designation for MASH
September 16, 2024
Topline results from Boehringer's Phase III IPF Study
September 09, 2024
Positive results reported in HER2 mutated lung cancer
August 27, 2024
Boehringer Ingelheim to unveil oncology research at WCLC
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
July 18, 2024
New affordability initiative with GoodRx for our biosimilar
July 17, 2024
New effort to help improve C-R-M health outcomes
June 07, 2024
Results from Phase II MASH trial presented at EASL 2024
June 01, 2024
Boehringer inhalers now available at $35 a month for eligible patients
May 13, 2024
New agreement with Quallent expands biosimilar access
May 02, 2024
Improving Access to Clinical Trials
May 01, 2024
FDA Approves Additional Formulation of Our Biosimilar
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline.
April 06, 2024
Results announced from EMPACT-MI phase III trial
March 19, 2024
New FDA approval for the treatment of GPP
March 12, 2024
Update on sNDA for fibrosing ILD in children and adolescents
March 07, 2024
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
February 26, 2024
Top-line Phase II Data for treatment of MASH
November 20, 2023
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
November 10, 2023
Investigational Compound Granted FDA Orphan Drug Designation
November 06, 2023
Promising Phase II Results in Chronic Kidney Disease
November 04, 2023
AI-Driven Model Validated to Predict Risk of CKD Progression
November 01, 2023
Hip-Hop Classic “It Takes Two” Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
October 27, 2023
Boehringer Ingelheim wins 2023 Prix Galien USA
October 02, 2023
Low-WAC interchangeable biosimilar is now available
September 22, 2023
FDA Approved Treatment Option for Adults with CKD
August 28, 2023
Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program
August 02, 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
July 25, 2023
FDA accepts OFEV sNDA for 6–17-year-olds with fibrosing ILD
July 13, 2023
Interchangeable Biosimilar Now on Express Scripts® Formulary
July 04, 2023
Boehringer Ingelheim presents Effisayil™ 2 trial results
July 01, 2023
Interchangeable biosimilar now available in the U.S.
June 28, 2023
Boehringer Ingelheim and FIT Unveil Fifth Piece for The Unwearable Collection
June 23, 2023
Optum Rx Places Interchangeable Biosimilar on its Commercial Formulary
June 21, 2023
FDA approves treatment option for T2D in children 10 and older
May 22, 2023
FDA approves autoinjector pen for Interchangeable biosimilar
May 09, 2023
IL-11 inhibitor antibody clinical development launched
May 02, 2023
U.S. FDA Grants Breakthrough Therapy designation
April 01, 2023
J-Code Issued for SPEVIGO
March 29, 2023
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
March 08, 2023
FDA accepts Jardiance sNDA for T2D in children 10 and older
March 06, 2023
Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines
February 28, 2023
Boehringer Ingelheim announces new partnership to support awareness of GPP
January 20, 2023
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease.
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
December 19, 2022
Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia
December 07, 2022
Full data announced in DINAMO trial in young people with T2D
November 16, 2022
Boehringer Ingelheim Welcomes New 2023 GOLD Report Positioning LAMA/LABA as the Preferred Treatment for the Majority of Patients with COPD
November 04, 2022
Full data announced in phase III EMPA-KIDNEY trial
October 26, 2022
First patient enrolled in FIBRONEER™-IPF Phase III trial
October 17, 2022
Boehringer Ingelheim announces expanded access program
September 25, 2022
Boehringer Ingelheim announces InPedILD PhaseIII trial results
September 21, 2022
Boehringer Ingelheim introduces Tune In To Lung Health
September 01, 2022
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
August 03, 2022
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
June 05, 2022
Real-world data announced for adults with type 2 diabetes
June 02, 2022
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
May 15, 2022
Investigational treatment slowed lung function decline in IPF
May 03, 2022
Boehringer Ingelheim Statement on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
April 20, 2022
Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
April 05, 2022
Boehringer Ingelheim strengthens investment in R&D
March 16, 2022
Phase III EMPA-KIDNEY trial will stop early
February 24, 2022
FDA Grants Breakthrough Therapy Designation for IPF
December 15, 2021
U.S. FDA grants priority review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare, life-threatening skin disease
December 13, 2021
Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner
November 16, 2021
Boehringer Ingelheim’s Carine Boustany Appointed to BIO Board
November 11, 2021
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
November 08, 2021
Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients
November 05, 2021
Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
October 27, 2021
Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia
October 26, 2021
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
October 25, 2021
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
October 19, 2021
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
October 15, 2021
U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
October 04, 2021
Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals
September 21, 2021
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches
September 16, 2021
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
September 09, 2021
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
September 09, 2021
FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction
August 27, 2021
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
August 18, 2021
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
August 03, 2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
July 06, 2021
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
June 02, 2021
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
May 24, 2021
Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia Receives FDA Breakthrough Therapy Designation
May 14, 2021
Study analysis available during ATS 2021 supports long-term treatment with Ofev® in patients with systemic sclerosis-associated interstitial lung disease
May 11, 2021
Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners
May 10, 2021
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
May 05, 2021
Baseball Legend Bernie Williams Calls on the Public to Join Queen Latifah, The Bacon Brothers, Paul Shaffer, as Judges of the Breathless® Ballad Challenge
April 14, 2021
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
April 13, 2021
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
March 31, 2021
Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care
March 24, 2021
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
March 16, 2021
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
March 01, 2021
Boehringer Ingelheim and Gubra Join Forces to Identify and Validate Innovative Peptides for the Treatment of Obesity
January 12, 2021
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
January 11, 2021
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
January 11, 2021
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
December 15, 2020
Jardiance® associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
December 10, 2020
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
December 09, 2020
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
December 07, 2020
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
November 30, 2020
Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E
November 19, 2020
Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection
November 18, 2020
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
November 05, 2020
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Pharmaceuticals, Inc.
October 30, 2020
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim
Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim
Pharmaceuticals, Inc.
October 23, 2020
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
October 15, 2020
Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure
October 14, 2020
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
October 13, 2020
IASLC NACLC 2020: Boehringer Ingelheim presents new data for Gilotrif® in metastatic, squamous cell carcinoma of the lung, and in EGFR mutation-positive NSCLC
October 01, 2020
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
September 17, 2020
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION IN KRAS
September 15, 2020
US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack
September 14, 2020
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
September 11, 2020
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
September 10, 2020
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
September 02, 2020
Final analysis of the observational GioTag study: Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small cell lung cancer
August 29, 2020
Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure with reduced ejection fraction
August 27, 2020
Boehringer Ingelheim Announces U.S. Country Managing Director Jean-Michel Boers Appointed to PhRMA Board of Directors
August 18, 2020
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
August 12, 2020
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
August 10, 2020
New Analyses of Ofev® data in patients with chronic fibrosing ILDs available during American Thoracic Society Congress
August 10, 2020
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
July 30, 2020
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
July 07, 2020
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
July 02, 2020
Boehringer Ingelheim Launches External Innovation Hub in China
June 19, 2020
Full results from EMPERIAL exercise ability trials presented
June 15, 2020
Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire
June 08, 2020
New consortium EUbOPEN will provide tools to unlock disease biolog
May 26, 2020
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
May 14, 2020
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
May 13, 2020
Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide
April 08, 2020
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
April 07, 2020
American Thoracic Society Announces that Boehringer Ingelheim is the First Donor of its COVID‐19 Crisis Fund
April 06, 2020
Boehringer Ingelheim, Sodexo and Food Rescue US Collaborate to Nourish Fairfield County’s Food Insecure in Response to the COVID-19 Crisis
March 12, 2020
US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease
March 09, 2020
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
February 27, 2020
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
January 27, 2020
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
January 09, 2020
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
November 17, 2019
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
November 13, 2019
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
November 12, 2019
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
October 29, 2019
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
October 10, 2019
FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
September 30, 2019
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
September 20, 2019
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
September 06, 2019
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
September 04, 2019
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
September 03, 2019
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
August 12, 2019
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
August 05, 2019
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
August 01, 2019
First half 2019: High levels of investment in R&D and robust organic growth
July 25, 2019
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
July 15, 2019
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
July 08, 2019
New data show efficacy and safety of Pradaxa® in the management of VTE in children
July 01, 2019
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R and D Pipeline With New First-in-Class Compound from Yuhan Corporation
June 26, 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
BI 765063, in Patients with Advanced Solid Tumors
June 17, 2019
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody,
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody,
BI 765063, in Patients with Advanced Solid Tumors
June 11, 2019
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
June 10, 2019
New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria
June 04, 2019
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
May 29, 2019
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
May 14, 2019
Boehringer Ingelheim announces resolution of Cyltezo® patent litigation
Boehringer Ingelheim grows and invests
April 17, 2019
Financial year 2018:
Financial year 2018:
Boehringer Ingelheim grows and invests
March 29, 2019
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
March 22, 2019
World Water Day - Making every drop count
March 07, 2019
Novel antibody shows potential to transform treatment of rare form of psoriasis
February 14, 2019
Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
January 03, 2019
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
December 13, 2018
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
November 26, 2018
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
November 05, 2018
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
October 22, 2018
Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
October 11, 2018
FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
Media Contacts
Head, U.S. Communications Human Pharma
900 Ridgebury Rd.
P.O. Box 368
Ridgefield, CT 06877
Boehringer Ingelheim Animal Health USA Inc.
U.S. Communications
Phone +1 (516) 527-5456